Allison B. Chambliss

Allison B. Chambliss

Auto-generated profile, based on publicly available information

Allison B. Chambliss

Department of Pathology & Laboratory Medicine David Geffen School of Medicine at UCLA Los Angeles California USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2013 in Scientific Reports
Verified
Journal Article
Open access
PDF file
ACAllison B. Chambliss
Allison B. Chambliss
SKShyam B. Khatau
Shyam B. Khatau
NENicholas Erdenberger
Nicholas Erdenberger
DRD. Kyle Robinson
D. Kyle Robinson
DHDidier Hodzic
Didier Hodzic
DWDenis Wirtz
Denis Wirtz
Cells continuously sense and respond to external mechanical forces through their cytoskeleton. Here we show that only a small subset of actin fibers, those forming the perinuclear actin cap that wraps around the nucleus, form in response to low physiological mechanical stresses in adherent fibroblasts. While conventional basal stress fibers form only past a threshold shear stress of 0.5 dyn/cm2, actin-cap fibers are formed at shear stresses 50 times lower and orders-of-magnitude faster than biochemical stimulation. This fast differential response is uniquely mediated by focal adhesion protein zyxin at low shear stress and actomyosin fibers of the actin cap. We identify additional roles for lamin A/C of the nuclear lamina and linkers of nucleus to cytoskeleton (LINC) molecules nesprin2giant and nesprin3, which anchor actin cap fibers to the nucleus. These results suggest an interconnected physical pathway for mechanotransduction, from the extracellular milieu to the nucleus.

7 May 2013 in Soft Matter
Verified
Journal Article
Closed access
PDF file
DKDong-Hwee Kim
Dong-Hwee Kim
ACAllison B. Chambliss
Allison B. Chambliss
DWDenis Wirtz
Denis Wirtz
The perinuclear actin cap (or actin cap) is a recently characterized cytoskeletal organelle composed of thick, parallel, and highly contractile acto-myosin filaments that are specifically anchored to the apical surface of the interphase nucleus. The actin cap is present in a wide range of adherent eukaryotic cells, but is disrupted in several human diseases, including laminopathies and cancer. Through its large terminating focal adhesions and anchorage to the nuclear lamina and nuclear envelope through LINC complexes, the perinuclear actin cap plays a critical role both in mechanosensation and mechanotransduction, the ability of cells to sense changes in matrix compliance and to respond to mechanical forces, respectively.

25 April 2016 in Oncogene
Verified
Journal Article
Closed access
PDF file
MSM Y Shah
M Y Shah
EME Martinez-Garcia
E Martinez-Garcia
JPJ M Phillip
J M Phillip
ACA B Chambliss
A B Chambliss
RPR Popovic
R Popovic
JLJonathan D. D Licht
Jonathan D. D Licht

1 May 2023 in The Journal of Applied Laboratory Medicine
Verified
Journal Article
Open access
PDF file
ACAllison B Chambliss
Allison B Chambliss
KPKhushbu Patel
Khushbu Patel
JCJessica M Colón-Franco
Jessica M Colón-Franco
JHJoshua Hayden
Joshua Hayden
SKSophie E Katz
Sophie E Katz
AWAlison Woodworth
Alison Woodworth
Background: Procalcitonin (PCT), a peptide precursor of the hormone calcitonin, is a biomarker whose serum concentrations are elevated in response to systemic inflammation caused by bacterial infection and sepsis. Clinical adoption of PCT in the United States has only recently gained traction with an increasing number of Food and Drug Administration–approved assays and expanded indications for use. There is interest in the use of PCT as an outcomes predictor as well as an antibiotic stewardship tool. However, PCT has limitations in specificity, and conclusions surrounding its utility have been mixed. Further, there is a lack of consensus regarding appropriate timing of measurements and interpretation of results. There is also a lack of method harmonization for PCT assays, and questions remain regarding whether the same clinical decision points may be used across different methods. Content: This guidance document aims to address key questions related to the use of PCT to manage adult, pediatric, and neonatal patients with suspected sepsis and/or bacterial infections, particularly respiratory infections. The document explores the evidence for PCT utility for antimicrobial therapy decisions and outcomes prediction. Additionally, the document discusses analytical and preanalytical considerations for PCT analysis and confounding factors that may affect the interpretation of PCT results. Summary: While PCT has been studied widely in various clinical settings, there is considerable variability in study designs and study populations. Evidence to support the use of PCT to guide antibiotic cessation is compelling in the critically ill and in some lower respiratory tract infections but is lacking in other clinical scenarios, and evidence is also limited in the pediatric and neonatal populations. Interpretation of PCT results requires guidance from multidisciplinary care teams of clinicians, pharmacists, and clinical laboratorians.

28 March 2013 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
ACAllison B. Chambliss
Allison B. Chambliss
PWPei‐Hsun Wu
Pei‐Hsun Wu
WCWei‐Chiang Chen
Wei‐Chiang Chen
SSSean X. Sun
Sean X. Sun
DWDenis Wirtz
Denis Wirtz
Heterogeneity of cellular phenotypes in asynchronous cell populations placed in the same biochemical and biophysical environment may depend on cell cycle and chromatin modifications; however, no current method can measure these properties at single‐cell resolution simultaneously and in situ. Here, we develop, test, and validate a new microscopy assay that rapidly quantifies global acetylation on histone H3 and measures a wide range of cell and nuclear properties, including cell and nuclear morphology descriptors, cell‐cycle phase, and F‐actin content of thousands of cells simultaneously, without cell detachment from their substrate, at single‐cell resolution. These measurements show that isogenic, isotypic cells of identical DNA content and the same cell‐cycle phase can still display large variations in H3 acetylation and that these variations predict specific phenotypic variations, in particular, nuclear size and actin cytoskeleton content, but not cell shape. The dependence of cell and nuclear properties on cell‐cycle phase is assessed without artifact‐prone cell synchronization. To further demonstrate its versatility, this assay is used to quantify the complex interplay among cell cycle, epigenetic modifications, and phenotypic variations following pharmacological treatments affecting DNA integrity, cell cycle, and inhibiting chromatin‐modifying enzymes.—Chambliss, A. B., Wu, P.‐H., Chen, W.‐C., Sun, S. X., Wirtz, D. Simultaneously defining cell phenotypes, cell cycle, and chromatin modifications at single‐cell resolution. FASEB J. 27, 2667‐2676 (2013). www.fasebj.org

14 February 2019 in Clinical Chemistry and Laboratory Medicine (CCLM)
Verified
Journal Article
Closed access
PDF file
ACAllison B. Chambliss
Allison B. Chambliss
JHJoshua Hayden
Joshua Hayden
JCJennifer M. Colby
Jennifer M. Colby
Background: Procalcitonin (PCT) is a biomarker for systemic bacterial infections and may aid in decision making for antimicrobial stewardship. Numerous PCT assays are available on common clinical immunoassay platforms. However, questions remain about the harmonization of these assays and whether the same clinical decision points may be used with all methods. Methods: Thirty-seven remnant patient serum samples were analyzed across four different PCT assays: Abbott ARCHITECT i2000, bioMérieux MINI VIDAS, Roche Elecsys cobas e 411, and BRAHMS KRYPTOR. Regression analysis was performed, and correlation was assessed at common clinical decision points for antimicrobial therapy: 0.10, 0.25, and 0.50 μg/L. Results: Data showed a positive bias of the MINI VIDAS compared to the KRYPTOR (slope=1.188, R=0.9873) and negative biases of both the ARCHITECT i2000 and cobas e 411 compared to the KRYPTOR (slope=0.806, R=0.8864, and slope=0.795, R=0.8974, respectively). A comparison of results at commonly used clinical decision points for antimicrobial stewardship showed that, relative to the KRYPTOR, 21% of samples would be classified into different interpretive categories by the ARCHITECT i2000 method, 31% of samples would be classified differently by the MINI VIDAS method, and 16% of samples would be classified differently by the cobas e 411 method. Conclusions: All methods showed reasonable analytical agreement; however, an analysis of result interpretation at clinical decision points showed that many samples were differentially categorized (e.g. shifted by one interpretive category) by the methods. Overall, our findings support a need for harmonization of PCT methods. Until then, institutions should independently evaluate their PCT assays against predicate methods and consider the impact on result interpretation prior to incorporating PCT into clinical practice.